as a setting to address HCV: current practice and future capacity
Authors: Vendula Belackova1 , Allison M. Salmon1 , Eberhard Schatz2 , Marianne Jauncey1
On behalf of the International Network of Drug Consumption Rooms
1 Uniting Sydney Medically Supervised Injecting Centre (MSIC), Sydney, Australia,
2 CORRELATION Network, Foundation De REGENBOOG GROEP, Amsterdam, the Netherlands
Drug consumption rooms (DCRs) and supervised injecting facilities (SIFs) target the most vulnerable people who use drugs (PWUD) – particularly people who use opioids, people who inject drugs (PWID), people who use drugs heavily or high-risk drug users (HRDI) . While decreases in risky injecting behaviours are an outcome of DCR use, HCV prevention and treatment in these settings haven’t been adequately described. There are no international DCR standards for HCV practice and surveys are yet to address HCV prevention, treatment or sero-prevalence status of DCR clients. This online survey provides a ‘snapshot’ of DCR clients’ HCV status; approaches to HCV in DCRs, and what DCRs need to expand these services.
